Medical information Clinical review pending

Genetic Testing

APP Gene Cerebral Amyloid Angiopathy APP Related Genetic Test

Genetic test using Next-Generation Sequencing (NGS) to identify variations in the APP gene associated with cerebral amyloid angiopathy (CAA). Helps assess risk for related neurological conditions.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question

Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample: Blood sample (collected in an EDTA tube), Extracted DNA, or One drop of blood on an FTA card.
Results: Confirm with the laboratory before booking.
Preparation: A detailed clinical history of the patient is required. A genetic counseling session is recommended prior to testing to discuss the implications, benefits, and limitations, and to draw a pedigree chart of affected family members.

Test priceKSh 40,000

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the APP Gene Cerebral Amyloid Angiopathy APP Related Genetic Test test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

Insurer or scheme name & policy / member number
A clinician's request / prescription for the test
Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

Full name *

Mobile number *

+254

Insurer or scheme

Policy / member number (optional)

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

WhatsApp the claims team Call us

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

✓Family history of cerebral amyloid angiopathy (CAA)
✓Family history of early-onset Alzheimer's disease
✓Unexplained recurrent strokes
✓Cognitive decline with suspected vascular component
✓Individuals seeking genetic risk assessment for CAA
✓Patients with diagnosed CAA seeking genetic confirmation

In plain language

What this test helps you understand

This test helps identify genetic variations in the APP gene linked to cerebral amyloid angiopathy (CAA). It can aid in understanding an individual's risk for developing CAA and related neurological conditions, potentially informing clinical management and family planning.

The APP Gene Cerebral Amyloid Angiopathy APP Related NGS Genetic DNA Test is a specialized diagnostic tool designed to assess genetic variations associated with cerebral amyloid angiopathy (CAA). CAA is a condition where amyloid protein builds up in the walls of brain arteries, potentially leading to serious neurological issues like stroke or cognitive decline. This test uses advanced Next-Generation Sequencing (NGS) technology to provide a detailed analysis of the APP gene, which plays a key role in the development of CAA. By identifying specific mutations or variations in this gene, healthcare providers can gain valuable insights into an individual's genetic predisposition to CAA and related neurological disorders. This information can be crucial for understanding risk, guiding health management, and informing family members about potential inherited risks.

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

Speak with us

We check the test and answer your questions before collection.

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

Understand your report

A counselor helps you understand the result and the next steps.

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →

PreparationA detailed clinical history of the patient is required. A genetic counseling session is recommended prior to testing to discuss the implications, benefits, and limitations, and to draw a pedigree chart of affected family members.

SampleBlood sample (collected in an EDTA tube), Extracted DNA, or One drop of blood on an FTA card.

MethodologyNext-Generation Sequencing (NGS) targeting the APP gene.

PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.

This test analyzes specific regions of the APP gene. It may not detect all possible genetic variations associated with CAA. Results should be interpreted alongside clinical findings and family history. A negative result does not completely rule out the possibility of CAA.

Read your report

What common result terms mean

TermPlain-language meaning

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.

NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.

VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.

Questions people ask

Frequently asked questions

CAA is a condition where amyloid protein builds up in the walls of blood vessels in the brain. This can weaken the vessels and increase the risk of bleeding, stroke, and cognitive impairment.

Individuals with a family history of CAA, early-onset Alzheimer's disease, recurrent strokes, or unexplained cognitive decline may benefit from this test. Genetic counseling is recommended to determine suitability.

The test looks for specific genetic variations (mutations) in the APP gene that are known to be associated with an increased risk of developing CAA.

Results should be discussed with a healthcare provider, ideally a neurologist or genetic counselor. They can explain the findings in the context of your personal and family medical history.

While not always mandatory, genetic counseling before and after the test is highly recommended to understand the implications of the results and discuss potential risks for family members.

A blood sample, extracted DNA, or a single drop of blood on an FTA card can be used for this test.

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

ACMG/AMP technical standards for sequence variant interpretation
ClinGen curation and gene–disease validity frameworks where applicable
LOINC-coded reporting for interoperable results
ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

Last updated: September 27, 2026
Medical review: not yet completed
Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →

Chat on WhatsApp